The Trump administration’s 2025 trade agenda is compelling US medical device companies to address escalating tariff pressures, especially those on imports from China. While some are making decisive shifts in their manufacturing strategies, others are conservatively absorbing short-term impacts and awaiting tariff stabilization. As such, firms must carefully evaluate the long-term risks of trade disruption as they assess strategies for policy resilience protecting their market position, says GlobalData, a leading data and analytics company.
Diversifiers moving quickly to localize operations
Abbott Laboratories, which earns over 60% of its revenue internationally, is investing $500 million to expand US manufacturing in Illinois and Texas. Similarly, Johnson & Johnson announced a 25% increase in US investment in March, committing more than $55 billion over four years to strengthen its domestic manufacturing and R&D.
Ashley Clarke, Senior Medical Analyst at GlobalData, comments: “Even when not directly tied to tariffs, these capital-heavy moves align with a broader trend toward self-reliance in US markets, preparing for potential regulation changes beyond 2025. These companies are proactively preparing for the future, safeguarding revenues in the world’s largest medical device market.”
Delayers avoid structural shifts in hopes of stabilization
GE HealthCare expects a $475 million EBIT impact in 2025, with 75% from US-China tariffs, but is not shifting its capital strategy. Instead, it’s focusing on automation and productivity improvements, and maintaining R&D pipelines. Stryker, anticipating a $200 million impact, is similarly focusing on internal efficiencies while closely monitoring the trade environment and making no commitments to capital reallocation.
Clarke continues: “These companies are essentially buying time, hoping that the policy environment will stabilize, sparing them from costly overhauls. But this strategy leaves them more vulnerable if tariffs remain in place.”
Dual-planners poised to employ a balanced approach
Medtronic shut down more than a dozen global manufacturing and distribution sites in 2024 to enhance margins. Its tariff strategy for 2025 involves monitoring tensions, optimizing operations, and reassessing its global footprint—without making additional restructuring commitments.
Clarke adds: “Medtronic’s strategy reflects calculated flexibility. The company has shown it’s willing to restructure aggressively when necessary, but for now they are reserving major changes until the trade picture becomes clearer.”
Clarke concludes: “Tariffs have shifted from a cost consideration to a strategic factor that could influence manufacturing, R&D, and investment timelines throughout the MedTech sector. Companies with localized production capabilities or robust sourcing models are anticipated to be in the best position to withstand future disruptions.”
